ImageneBio, Inc. cotiza a 4.24 USD y tiene una capitalización bursátil de $48M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding…
| Periodo | 2026-08 | 2026-05 | 2025-11 |
|---|---|---|---|
| Real | $-0.63 | $-0.95 | $-2.91 |
| Estimado | $-0.98 | $-0.66 | $-1.00 |
| Sorpresa | +35.7% | -43.9% | -191.0% |
| Métrica | IMA | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -6056.4% | -38.6% | -6017.8% |
| Net Margin | -5668.6% | -33.6% | -5635.1% |
| FCF Margin | — | -13.9% | — |
| ROE | -34.1% | -40.4% | +6.3% |
| ROA | -29.6% | -32.0% | +2.4% |
| Current Ratio | 12.49 | 2.84 | +9.65 |
| Debt / Equity | — | 0.28 | — |